Oramed Pharmaceuticals Inc., a New York-based biopharmaceutical company, is making strides in the development of innovative solutions for individuals with diabetes. The company's product portfolio includes orally ingestible insulin capsules, such as ORMD-0801 Type 2, which has completed phase II clinical trials. Additionally, Oramed is working on a phase 2 oral insulin capsule for the treatment of non-alcoholic steatohepatitis, a progressive liver disease, and an oral glucagon-like peptide-1 capsule for type 2 diabetes, ORMD-0901, which has completed phase I clinical trials. Since its incorporation in 2002, Oramed has been dedicated to advancing medical treatments for diabetes and is a trailblazer in the field of orally ingestible capsules for the delivery of polypeptides.
Oramed Pharmaceuticals Inc.'s ticker is ORMP
The company's shares trade on the NASDAQ stock exchange
They are based in Jerusalem, Israel
There are 11-50 employees working at Oramed Pharmaceuticals Inc.
It is https://www.oramed.com/
Oramed Pharmaceuticals Inc. is in the Healthcare sector
Oramed Pharmaceuticals Inc. is in the Biotechnology industry
The following five companies are Oramed Pharmaceuticals Inc.'s industry peers: